(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

RDCURE

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: WordOffice: United States

Quick snapshot

RDCURE

ST13

US500000097215495

Class

44

Filing

97215495

Registration

8187896

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

38

Latest update

03/25/2026

Trademark type

Word

Nice classes

44

Filing date

01/12/2022

Registration date

03/24/2026

Expiration date

-

Complete case details

Structured fields from the responsible authority and the official record.

Status date

03/24/2026

Last transaction

03/25/2026

Responsible office

United States Patent and Trademark Office

Status code

700

Official register

Principal Register

Filing basis

Intent to use

First use anywhere

05/16/2023

First use in commerce

05/16/2023

Drawing code

4

Owner type

16

Owner location

Philadelphia, PA, US

Examiner

GLUECK, CHRISTOPHER N

Law office

M30

Current location

PUBLICATION AND ISSUE SECTION

Holders and representatives

Holders

RDCure LLC

Representatives

Christiane S. Campbell DUANE MORRIS LLP

Technical classification

Nice Classes

Class 44

Vienna Codes

No Vienna codes available.

Goods and services

Class 44

Providing information relating to pharmaceuticals and gene therapies; Pharmaceutical advice; Providing medical advice in the field of gene therapy; Pharmaceutical and gene therapy consultation

Publications

History of USPTO decisions and trademark events.

38 publications found

NRCC

NOTICE OF REGISTRATION CONFIRMATION EMAILED

03/24/2026

R.PR

REGISTERED-PRINCIPAL REGISTER

03/24/2026

SUNA

NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED

03/03/2026

CNPR

ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED

03/03/2026

SUPC

STATEMENT OF USE PROCESSING COMPLETE

03/03/2026

AITU

CASE ASSIGNED TO INTENT TO USE PARALEGAL

03/03/2026

IUAF

USE AMENDMENT FILED

08/27/2025

EISU

TEAS STATEMENT OF USE RECEIVED

08/27/2025

EXRA

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

03/05/2025

EX3G

SOU EXTENSION 3 GRANTED

03/04/2025

EXT3

SOU EXTENSION 3 FILED

03/04/2025

EEXT

SOU TEAS EXTENSION RECEIVED

03/04/2025

EXRA

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

09/09/2024

EX2G

SOU EXTENSION 2 GRANTED

09/09/2024

EXT2

SOU EXTENSION 2 FILED

09/09/2024

EEXT

SOU TEAS EXTENSION RECEIVED

09/09/2024

EXRA

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

02/27/2024

EX1G

SOU EXTENSION 1 GRANTED

02/24/2024

EXT1

SOU EXTENSION 1 FILED

02/24/2024

EEXT

SOU TEAS EXTENSION RECEIVED

02/24/2024

NOAM

NOA E-MAILED - SOU REQUIRED FROM APPLICANT

09/12/2023

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

07/18/2023

PUBO

PUBLISHED FOR OPPOSITION

07/18/2023

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

06/28/2023

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

06/08/2023

XAEC

EXAMINER'S AMENDMENT ENTERED

06/05/2023

GNEN

NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED

06/05/2023

GNEA

EXAMINERS AMENDMENT E-MAILED

06/05/2023

CNEA

EXAMINERS AMENDMENT -WRITTEN

06/05/2023

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

04/20/2023

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

04/20/2023

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

04/20/2023

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

10/20/2022

GNRT

NON-FINAL ACTION E-MAILED

10/20/2022

CNRT

NON-FINAL ACTION WRITTEN

10/20/2022

DOCK

ASSIGNED TO EXAMINER

10/19/2022

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

01/19/2022

NWAP

NEW APPLICATION ENTERED

01/15/2022

Continuous trademark protection

Get notified about every new filing that threatens RDCURE or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.